ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

Pfizer PFE reported first-quarter 2025 adjusted earnings per share of 92 cents, which comprehensively beat the Zacks ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Victorian babies will be safer from Respiratory Syncytial Virus (RSV) this winter, with a long-acting immunisation available ...

The long-acting Respiratory Syncytial Virus (RSV) immunisation is now available free for eligible families until September 30 ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...